Abstract
Importance Expansion in the clinical use of genetic and genomic testing has led to a recognition that these tests provide personal as well as clinical utility to patients and families. It is essential to ensure that members of diverse sociodemographic backgrounds are included in defining and measuring personal utility.
Objective To determine the demographics of participants contributing to the development of a definition of personal utility for genetic and genomic testing.
Evidence Review We searched PubMed, Scopus, Web of Science, and Embase for peer-reviewed literature published between 2003 and January 2022 on the personal utility of genetic or genomic sequencing. Our review included both qualitative and quantitative studies with samples that included patients, their family members, or the general public. Eligible studies could examine any clinical genetic or genomic test and required the use of the term “utility.” Authors extracted and reviewed study and participant characteristics including number of participants, study location (U.S. or international), primary methodology (qualitative or quantitative), race and ethnicity, gender, income and education data.
Findings Our final review included 53 studies and 13,315 total participants. Gender was provided for 95.6% of participants (n=12,724), of whom 61.5% were female (n=7,823). Race and/or ethnicity was provided for 83.0% of participants (n=11,048), of whom 82.2% (n=9,083) were White. The remaining participants were identified as Hispanic/Latinx (5.5%, n=607), Asian American and Pacific Islander (3.8%, n=421), Black (3.5%, n=387), multiracial (0.2%, n=27), and various other racial or ethnic categories (3.7%, n=412). Educational attainment was reported for 82.6% of participants. Among these participants, 71.2% (n=7,830) had a bachelor’s degree or higher. Income was reported for 66.5% of participants (n=8,857), and 66% of these participants (n=5,831) reported income above the U.S. median.
Conclusions and Relevance Our results suggest that the concept of personal utility in genetic and genomic testing in the U.S. is disproportionately defined by the perspectives a narrow subset of the population – specifically non-Hispanic White, well-educated women with above-average household incomes. If we are to provide equitable care in the areas of genomics and genetics, we will need to expand research to include more diverse and representative samples.
Question What are the demographic characteristics of participants contributing to a definition of personal utility in genetic and genomic testing?
Findings This systematic review included 53 studies and13,315 total participants. Demographic characteristics on gender were provided for 95.6% of participants, race and/or ethnicity for 83.0% of participants, educational attainment for 82.6% of participants, and income for 66.5% of participants. Participants were 61.5% female, 82.2% White, 71.2% had a bachelor’s degree or higher, and 66% reported income above the U.S. median.
Meaning Our understanding of the utility of genetics and genomics lacks the perspectives of people with diverse sociodemographic characteristics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
M.C.H is supported by a grant from National Human Genome Research Institute K01HG011341. J.L.Y is supported by American Heart Association grant number 19SFRN34830054.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a systematic review and the sources of the data consisted only of published manuscripts.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
